These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 34290709)

  • 1. Bispecific Antibody Armed Metabolically Enhanced Headless CAR T Cells.
    Thakur A; Scholler J; Kubicka E; Bliemeister ET; Schalk DL; June CH; Lum LG
    Front Immunol; 2021; 12():690437. PubMed ID: 34290709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced cytotoxicity against solid tumors by bispecific antibody-armed CD19 CAR T cells: a proof-of-concept study.
    Thakur A; Scholler J; Schalk DL; June CH; Lum LG
    J Cancer Res Clin Oncol; 2020 Aug; 146(8):2007-2016. PubMed ID: 32449004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-tumor and immune modulating activity of T cell induced tumor-targeting effectors (TITE).
    Thakur A; Kondadasula SV; Ji K; Schalk DL; Bliemeister E; Ung J; Aboukameel A; Casarez E; Sloane BF; Lum LG
    Cancer Immunol Immunother; 2021 Mar; 70(3):633-656. PubMed ID: 32865605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Broad reactivity and enhanced potency of recombinant anti-EGFR × anti-CD3 bispecific antibody-armed activated T cells against solid tumours.
    Huang MTF; Sharma V; Mendelsohn A; Wei Q; Li J; Yu B; Larrick JW; Lum LG
    Ann Med; 2022 Dec; 54(1):1047-1057. PubMed ID: 36799362
    [No Abstract]   [Full Text] [Related]  

  • 5. [Construction of CD138-targeted chimeric antigen receptor- modified T cells and their effect in multiple myeloma therapy].
    Guo CC; Lu Y; Tang KJ; Xing HY; Tian Z; Rao Q; Wang M; Xiong DS; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2024 May; 45(5):436-444. PubMed ID: 38964917
    [No Abstract]   [Full Text] [Related]  

  • 6. Integrin β4-Targeted Cancer Immunotherapies Inhibit Tumor Growth and Decrease Metastasis.
    Ruan S; Lin M; Zhu Y; Lum L; Thakur A; Jin R; Shao W; Zhang Y; Hu Y; Huang S; Hurt EM; Chang AE; Wicha MS; Li Q
    Cancer Res; 2020 Feb; 80(4):771-783. PubMed ID: 31843981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical delayed toxicity studies of BCMA CAR T-cell injection in B-NDG mice with multiple myeloma.
    Guo J; Wu Q; Li H; Liang C; Dai J; Zhang S; Dai C; Zhang J; Wen Y; Yang W
    Front Immunol; 2024; 15():1435934. PubMed ID: 39606226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells.
    Urbanska K; Lynn RC; Stashwick C; Thakur A; Lum LG; Powell DJ
    J Transl Med; 2014 Dec; 12():347. PubMed ID: 25496493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significant Advancements and Evolutions in Chimeric Antigen Receptor Design.
    Gaimari A; De Lucia A; Nicolini F; Mazzotti L; Maltoni R; Rughi G; Zurlo M; Marchesini M; Juan M; Parras D; Cerchione C; Martinelli G; Bravaccini S; Tettamanti S; Pasetto A; Pasini L; Magnoni C; Gazzola L; Borges de Souza P; Mazza M
    Int J Mol Sci; 2024 Nov; 25(22):. PubMed ID: 39596267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Priming of pancreatic cancer cells with bispecific antibody armed activated T cells sensitizes tumors for enhanced chemoresponsiveness.
    Thakur A; Ung J; Tomaszewski EN; Schienschang A; LaBrie TM; Schalk DL; Lum LG
    Oncoimmunology; 2021 Jun; 10(1):1930883. PubMed ID: 34123574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0-2+) metastatic breast cancer.
    Lum LG; Al-Kadhimi Z; Deol A; Kondadasula V; Schalk D; Tomashewski E; Steele P; Fields K; Giroux M; Liu Q; Flaherty L; Simon M; Thakur A
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34117114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bispecific antibody-targeted T-cell therapy for acute myeloid leukemia.
    Kubicka E; Lum LG; Huang M; Thakur A
    Front Immunol; 2022; 13():899468. PubMed ID: 36389764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients.
    Lum LG; Thakur A; Choi M; Deol A; Kondadasula V; Schalk D; Fields K; Dufrense M; Philip P; Dyson G; Aon HD; Shields AF
    Oncoimmunology; 2020 Jun; 9(1):1773201. PubMed ID: 32939319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human airway macrophages are metabolically reprogrammed by IFN-γ resulting in glycolysis-dependent functional plasticity.
    Cox DJ; Connolly SA; Ó Maoldomhnaigh C; Brugman AAI; Sandby Thomas O; Duffin E; Gogan KM; Ó Gallchobhair O; Murphy DM; O'Rourke SA; O'Connell F; Nadarajan P; Phelan JJ; Gleeson LE; Basdeo SA; Keane J
    Elife; 2024 Dec; 13():. PubMed ID: 39620891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced cytotoxicity in multiple myeloma via T cells armed with bispecific T cell engager targeting B-cell maturation antigen on cancer cells and CD3 on T cells.
    Supimon K; Sangsuwannukul T; Luangwattananun P; Yenchitsomanus PT
    Int Immunopharmacol; 2024 Dec; 143(Pt 2):113480. PubMed ID: 39467352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Preparation of a dual-specific antibody targeting human CD123 and exploration of its anti-acute myeloid leukemia effects].
    Zhou T; Chen ML; Zhang CY; Liu XY; Wang ZZ; Xing HY; Tang KJ; Tian Z; Rao Q; Wang M; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):225-232. PubMed ID: 38716593
    [No Abstract]   [Full Text] [Related]  

  • 17. PTPRZ1-Targeting RNA CAR T Cells Exert Antigen-Specific and Bystander Antitumor Activity in Glioblastoma.
    Martinez Bedoya D; Marinari E; Davanture S; Castillo Cantero L; Erraiss S; Dockerill M; Barluenga S; Winssinger N; Schaller K; Bijlenga P; Momjian S; Voize C; Tissot SR; Kandalaft LE; Hammel P; Cosson P; Walker PR; Dutoit V; Migliorini D
    Cancer Immunol Res; 2024 Dec; 12(12):1718-1735. PubMed ID: 39269445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Logic-gated and contextual control of immunotherapy for solid tumors: contrasting multi-specific T cell engagers and CAR-T cell therapies.
    Nolan-Stevaux O; Smith R
    Front Immunol; 2024; 15():1490911. PubMed ID: 39606234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel anti-CD30/CD3 bispecific antibodies activate human T cells and mediate potent anti-tumor activity.
    Faber ML; Oldham RAA; Thakur A; Rademacher MJ; Kubicka E; Dlugi TA; Gifford SA; McKillop WM; Schloemer NJ; Lum LG; Medin JA
    Front Immunol; 2023; 14():1225610. PubMed ID: 37646042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel tri-specific T-cell engager targeting IL-13Rα2 and EGFRvIII provides long-term survival in heterogeneous GBM challenge and promotes antitumor cytotoxicity with patient immune cells.
    Park DH; Bhojnagarwala PS; Liaw K; Bordoloi D; Tursi NJ; Zhao S; Binder ZA; O'Rourke D; Weiner DB
    J Immunother Cancer; 2024 Dec; 12(12):. PubMed ID: 39622583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.